Skip to main content

Table 3 Breast cancer risk after cohort entry in distinct autoantibody strata, compared to the general population#

From: Association of systemic lupus erythematosus autoantibody diversity with breast cancer protection

Antibody Sample size No. obs. No. exp. SLE cohort SIR (95% CI) p value AA* SIR (95% CI) AA p value Non-AA^ SIR (95% CI) Non-AA p value
All 2431 22 34.9 0.63 (0.39–0.95) 0.027 1.13 (0.65–1.84) 0.69 0.29 (0.11–0.63) < 0.001
dsDNA 1503 12 21.7 0.55 (0.29–0.96) 0.035 0.97 (0.44–1.84) 0.99 0.24 (0.05–0.71) 0.003
RNP 709 9 7.3 1.24 (0.56–2.34) 0.62 1.78 (0.77–3.50) 0.17 0.36 (0.01–2.00) 0.47
Sm 507 2 4.9 0.41 (0.05–1.47) 0.27 0.34 (0.01–1.90) 0.42 0.51 (0.01–2.83) 0.83
Ro 756 4 10.2 0.39 (0.11–1.01) 0.053 0.23 (0.01–1.26) 0.13 0.52 (0.11–1.52) 0.35
La 313 0 4.7 0.00 (0.00–0.78) 0.018 0.00 (0.00–2.28) 0.40 0.00 (0.00–1.19) 0.09
LAC 615 4 11 0.37 (0.10–0.94) 0.031 0.92 (0.25–2.36) 0.99 0.00 (0.00–0.56) 0.003
ACL 1118 14 19.9 0.70 (0.38–1.18) 0.21 1.35 (0.67–2.42) 0.40 0.25 (0.05–0.74) 0.005
Beta2GP1 446 4 9 0.44 (0.12–1.13) 0.11 0.60 (0.07–2.17) 0.71 0.35 (0.04–1.27) 0.15
  1. #When adjusting for multiple comparisons (9 per racial strata), p ≤ 0.006 is considered statistically significant
  2. LAC lupus anticoagulant, ACL anticardiolipin, Beta2GP1 beta 2 glycoprotein 1, AA African American; non-AA non-African American
  3. *N = 966 SLE patients contributing 8488 person-years
  4. ^N = 1465 SLE patients contributing 11,911 person-years